Compare Quest Diagnostics Inc (DGX) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs IAC/Interactivecorp — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while IAC/Interactivecorp trades at $45.88 (market cap $3.37B). The key difference: Quest Diagnostics Inc is far larger — about 6.8× IAC/Interactivecorp's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.
| DGX | PPLI | |
|---|---|---|
Market Cap | $22.80B | $3.37B |
Sector | Health | Media |
52-Week High | $216.02 | $47.62 |
52-Week Low | $166.42 | $31.52 |
Enterprise Value | $28.82B | $3.68B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
PPLI trades at $45.89, down 1.31% today, with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company reported a net loss of $104.03M in 2025, missing earnings expectations for three consecutive quarters. Recent news indicates potential acquisition interest from MGM Resorts, adding speculative momentum. The stock's valuation metrics show a low P/B of 0.75 but a high P/E of 28.17, reflecting investor uncertainty about profitability.
The outlook is cautiously optimistic due to strong analyst support (63.64% buy ratings) and a $55.40 consensus price target, suggesting 21% upside. However, persistent earnings misses, negative cash flow trends, and high debt levels pose significant risks. Revenue decline from $5.2B in 2022 to $2.4B in 2025 highlights operational challenges that need addressing for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
